伊达比星联合甲氨蝶呤治疗原发中枢神经系统弥漫大B细胞淋巴瘤的临床效果研究

本研究旨在探讨伊达比星联合甲氨蝶呤治疗原发中枢神经系统弥漫大B细胞淋巴瘤的临床效果及安全性。选取2009年7月至2011年4月东南大学附属中大医院血液科及建湖县人民医院收治的原发性中枢神经系统弥漫大B细胞淋巴瘤患者88例,将采用伊达比星及甲氨蝶呤联合药物治疗的54例患者作为A组（观察组）,将采用甲氨蝶呤单纯药物治疗的34例患者作为B组（对照组）,比较2组的疗效。结果表明,A组CR 34例,PR 5例,总缓解率72.2%;B组CR 10例,PR 4例,总缓解率41.2%;A组较B组生存曲线有明显上升,而且A组平均生存期33.172个月,显著性高于B组的26.305个月（P〈0.05）。结论：伊达比星联合甲氨蝶呤治疗原发中枢神经系统弥漫大B细胞淋巴瘤临床效果满意,建议在临床治疗中推广应用。

Clinical Efficacy of Idarubicin Combined with Methotrexate for Treatment of Patients with Central Nervons System Diffuse Large B Cell Lymphoma

This study was aimed to investigate the clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B-cell lymphoma.A total of 88 patients with central nervous system diffuse large B-cell lymphoma was selectedout of them 54 patients received idarubicin combined with methotrexate and were selected as A groupother 34 patients received only methotrexate and were selected as B group（ control group）.Clinical efficacy and safety were compared after treatment.The results showed that in A group 84 patients achieved complete remission（ CR）,patients achived partial remission（ PR）,the total remission rate of A group was 72.2%in B group 10 patients achieved complete remission（CR）,patients achived partial remission（ PR）,the total remission rate of B group was 41.2%the average survival time of A group was 33.172 monthsand the average survival time of B group was 26.305 monthsthe former was significantly higher than latter（ P〈0.05）.It is concluded that idarubicin combined with methotrexate for the patients with central nervous system diffuse large B-cell lymphoma is effective and safeand may be used in clinec.